Use of Stimulants and Performance Enhancers During and After Trauma Exposure in a Combat Veteran: A Possible Risk Factor for Posttraumatic Stress Symptoms
Stimulant-Based Supplements: Difficult to Regulate, Easy Access
This case describes the onset and exacerbation of hyperarousal, panic, insomnia, and reexperiencing symptoms of PTSD with concomitant DMAA ingestion in a combat veteran. DMAA is a sympathomimetic amine stimulant (2) and is used as an ingredient in popular workout supplements marketed to promote weight loss and improve strength and performance. The patient was adherent with his SSRI regimen and outpatient therapy during the observed period, so it is possible that his symptom reduction resulted entirely from engagement in treatment. However, the temporal relationship between symptom onset and initiation of the supplement and remission of symptoms with discontinuation suggests an association, although causality cannot be established.
In response to numerous reports of adverse events associated with DMAA, including cardiac arrest, liver failure, hemorrhagic stroke, and death (2), the U.S. Food and Drug Administration banned products containing DMAA from the market in April 2013 (3). The Department of Defense prohibited DMAA use in military personnel and removed DMAA-containing products from military commissary shelves. While these actions have likely curtailed use of DMAA-containing products, DMAA and many other stimulant-containing nutritional supplements remain widely available to consumers and have been difficult to regulate (2). Examples of stimulant bodybuilding products available online include 1,3-dimethylbutylamine (DMBA) supplements such as “Frenzy” (Driven Sports) and “Contraband” (Iron Forged Nutrition) (4) and beta-methylphenylethylamine (BMPEA) products such as “Black Widow” (Hi-Tech Pharmaceuticals) and “Jet Fuel Superburn” (GAT) (5).
Performance-Enhancing Supplement and Stimulant Use in Active Duty Military Personnel and Veterans
Use of performance-enhancing supplements is widespread among younger generations of military personnel. Cross-sectional data from the Millennium Cohort Study, a survey of 106,698 active duty service members conducted from 2007 to 2008 during the wars in Afghanistan and Iraq, revealed that 46.7% of respondents reported use of bodybuilding, energy, and/or weight-loss supplements (6), and 22.0% reported use of multiple supplements. Among male respondents, the odds of using bodybuilding supplements were higher among those who were deployed (odds ratio=1.25; 95% CI=1.19, 1.31), those engaged in strength training (odds ratio=3.48; 95% CI=3.30, 3.67), and those born after 1980 (odds ratio=4.86; 95% CI=4.29, 5.50). A survey study of 329 active duty Marines deployed to Afghanistan found that 42% of female and 72% of male respondents reported supplement use while in the combat zone (7). In that study, 75% of supplement users reported use of stimulant-containing products.
Although less is known about supplement use in veterans, former service members may be likely to restart or continue supplement use after separation from the military. A retrospective longitudinal cohort analysis of Veterans Health Administration (VHA) records (N=496,722) revealed that 75% of treatment-seeking veterans of the Iraq and Afghanistan wars in VHA care are overweight or obese, and those with PTSD and depression were in the highest risk categories for obesity (8). Nutritional supplement manufacturers heavily market their products for weight loss, and former military personnel who used supplements during deployment may seek out these products after military service to lose weight.
In addition to supplements, prescription psychostimulants are also used in military settings to enhance performance and alertness, most commonly to combat fatigue in air force pilots (9). A Department of Defense survey of 28,546 military personnel reported an estimated past-year prevalence of prescription stimulant misuse of 2.3% (10). An anonymous survey of 498 active duty service members found that psychostimulant misuse in the past 5 years occurred at a rate of 5% and was associated with mental health conditions, deployment-related injuries, and new physical injuries (11).
Stimulant Use: A Risk Factor for PTSD?
In spite of the widespread use of stimulant-based supplements, little is known about the behavioral effects of chronic use of these products or whether they induce or exacerbate psychiatric symptoms. Stimulants in performance-enhancing supplements include amphetamines, caffeine, ephedrine, pseudoephedrine, and phenylephrine (12). Common behavioral effects of stimulants include increased alertness and wakefulness, anxiety, irritability, restlessness, mood swings, and psychosis (13).
At the time of a traumatic event, a cascade of noradrenergic signaling occurs in the brain, promoting the consolidation of fear-based memories in the amygdala (Figure 2). CNS stimulants, such as DMAA, trigger the release of dopamine, serotonin, and norepinephrine (14). If an individual is using stimulants at the time of a traumatic event, this may contribute to excessive noradrenergic activity during trauma, enhancing the encoding of the traumatic memory and subsequently leading to exaggerated fear responses (e.g., heightened arousal). Noradrenergic overactivation of the amygdala from stimulant use and enhancement of trauma-related memory consolidation may thus predispose trauma-exposed individuals to subsequent PTSD symptoms and may exacerbate PTSD symptoms in those already diagnosed with PTSD (15, 16).
It is unclear whether noradrenergic activation from stimulant use precipitates or worsens symptoms of PTSD. A recent analysis of medical and pharmacy records in active duty military personnel found a strong relationship between receipt of a prescription stimulant and later PTSD diagnosis at follow up several years later (hazard ratio=5.09, 95% CI=3.05, 8.50) (17). The study’s authors concluded that stimulant use may contribute to the pathogenesis of PTSD. Other preclinical data and a small (N=32) randomized controlled trial have found that psychostimulants may improve PTSD symptoms, possibly by enhancing learning, promoting a feeling of well-being, and targeting attention and concentration difficulties (14, 18, 19). Dopaminergic and serotonergic mechanisms may be implicated in the ameliorative effect of psychostimulants observed in these studies (14, 19). It is likely that the relationship between stimulants and PTSD symptoms varies depending on timing, quantity, and duration of stimulant use during or after traumatic exposures as well as individual genetic and environmental factors (17). Notably, the dose of stimulant is difficult to establish in unregulated supplement products, unlike in prescribed psychostimulants in therapeutic dosages. Many stimulant supplements have never been tested in humans, and their safety has not been established (4, 5). Some workout products, including “Jack3d,” which our patient used, contain caffeine and multiple other ingredients in addition to the amine stimulant. Prospective studies and larger randomized controlled trials are urgently needed to clarify the relationship between stimulant use and PTSD.
In the present case, the patient reported use of DMAA both during traumatic combat experiences in Iraq and about a year after his last deployment, when he restarted supplement use some 6 weeks before he presented for treatment. It is possible that stimulant use in the peritraumatic period made him vulnerable to developing PTSD symptoms, or that his PTSD symptoms worsened with the resumption of stimulant use after deployment. Off-label stimulant use from workout supplements may thus be a previously unknown risk factor for PTSD.
Conclusions
This case highlights the potential association between a stimulant-containing dietary supplement and PTSD symptom exacerbation in a recently returned college-age combat veteran. Noradrenergic overactivation in the amygdala and enhanced consolidation of traumatic memories may mediate the observed relationship between stimulant use and PTSD symptoms. While severe adverse effects of DMAA and other stimulant nutritional products have been described, the impact of DMAA on psychiatric symptoms, including PTSD, has not previously been reported. This case also highlights the importance of comprehensive assessment of dietary and herbal supplements in mental health settings. Given the popularity and continued availability of stimulant-containing nutritional supplements, health care providers should be aware of the potential behavioral effects of these products in addition to medical adverse effects. With increasing numbers of veterans seeking care in non-VA settings (20), mental health providers should be aware of the high prevalence of supplement use in this population. Screening for supplement use is especially important in high-risk groups, including young adults, athletes, high school and college students, military personnel, and veterans (6, 7, 12). Future studies will be critical in elucidating whether stimulant use during or after traumatic events contributes to the pathogenesis of PTSD.
Acknowledgments
Dr. Ellen Herbst has grants through the UCSF Hellman Fellows Fund, the Department of Defense, and a gift through Northern California Institute on Research and Education. Dr. Kalapatapu is currently funded by National Institute on Drug Abuse grant K23DA034883.
The views expressed in this article are those of the authors and do not reflect the official policy or position of the U.S. Department of Veterans Affairs.
References
1.
Blake DD, Weathers FW, Nagy LM, et al: The development of a Clinician-Administered PTSD Scale. J Trauma Stress 1995; 8:75–90
Karnatovskaia LV, Leoni JC, Freeman ML: Cardiac arrest in a 21-year-old man after ingestion of 1,3-DMAA-containing workout supplement. Clin J Sport Med 2015; 25:e23–e25
Cohen PA, Travis JC, Venhuis BJ: A synthetic stimulant never tested in humans, 1,3-dimethylbutylamine (DMBA), is identified in multiple dietary supplements. Drug Test Anal 2015; 7:83–87
Cohen PA, Bloszies C, Yee C, et al: An amphetamine isomer whose efficacy and safety in humans has never been studied, β-methylphenylethylamine (BMPEA), is found in multiple dietary supplements. Drug Test Anal 2016; 8:328–333.
Jacobson IG, Horton JL, Smith B, et al: Bodybuilding, energy, and weight-loss supplements are associated with deployment and physical activity in US military personnel. Ann Epidemiol 2012; 22:318–330
Maguen S, Madden E, Cohen B, et al: The relationship between body mass index and mental health among Iraq and Afghanistan veterans. J Gen Intern Med 2013; 28(suppl 2):S563–S570
Jeffery DD, Babeu LA, Nelson LE, et al: Prescription drug misuse among US active duty military personnel: a secondary analysis of the 2008 DoD survey of health related behaviors. Mil Med 2013; 178:180–195
Toledano D, Gisquet-Verrier P: Only susceptible rats exposed to a model of PTSD exhibit reactivity to trauma-related cues and other symptoms: an effect abolished by a single amphetamine injection. Behav Brain Res 2014; 272:165–174
Dębiec J, Bush DE, LeDoux JE: Noradrenergic enhancement of reconsolidation in the amygdala impairs extinction of conditioned fear in rats: a possible mechanism for the persistence of traumatic memories in PTSD. Depress Anxiety 2011; 28:186–193
O’Donnell T, Hegadoren KM, Coupland NC: Noradrenergic mechanisms in the pathophysiology of post-traumatic stress disorder. Neuropsychobiology 2004; 50:273–283
Aga-Mizrachi S, Cymerblit-Sabba A, Gurman O, et al: Methylphenidate and desipramine combined treatment improves PTSD symptomatology in a rat model. Transl Psychiatry 2014; 4:e447
Department of Veterans Affairs: Expanded access to non-VA care through the Veterans Choice Program: interim final rule. Fed Regist 2015; 80:74991–74996
From Mental Health Services, San Francisco VA Health Care System, San Francisco; the Department of Psychiatry, University of California, San Francisco; and the Dissemination and Training Division, National Center for PTSD, VA Palo Alto Health Care System, Menlo Park, Calif.
From Mental Health Services, San Francisco VA Health Care System, San Francisco; the Department of Psychiatry, University of California, San Francisco; and the Dissemination and Training Division, National Center for PTSD, VA Palo Alto Health Care System, Menlo Park, Calif.
From Mental Health Services, San Francisco VA Health Care System, San Francisco; the Department of Psychiatry, University of California, San Francisco; and the Dissemination and Training Division, National Center for PTSD, VA Palo Alto Health Care System, Menlo Park, Calif.
National Institute on Drug Abuse10.13039/100000026: K23DA034883
Department of Medicine, University of California, San Francisco10.13039/100008070: Hellman Foundation
The authors report no financial relationships with commercial interests.
Metrics & Citations
Metrics
Citations
Export Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.
For more information or tips please see 'Downloading to a citation manager' in the Help menu.
PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).
If the address matches an existing account you will receive an email with instructions to retrieve your username
Create a new account
Change Password
Password Changed Successfully
Your password has been changed
Login
Reset password
Can't sign in? Forgot your password?
Enter your email address below and we will send you the reset instructions
If the address matches an existing account you will receive an email with instructions to reset your password.
Change Password
Congrats!
Your Phone has been verified
×
As described within the American Psychiatric Association (APA)'s Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences. Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.